Tollovid – Maximum Strength 3CL Protease Inhibitor
Exploring Viral Persistence in PASC as a Target
-
100%
of Acute COVID respondents reported a decrease in symptoms.
-
93.7%
of PASC respondents reported a decrease in Long COVID Symptoms.
-
91.6%
of Short Long COVID respondents reported a decrease in fatigue.
Tollovid™ is a powerful proprietary blend of plant extracts that help support healthy immune function and it is the ONLY 3CL protease inhibitor available without a prescription.
-
Traceable Ingredients
-
Vegan Friendly
-
Scientifically Studied
-
Made in the USA
Latest News
View all-
Case Study 8: A Paxlovid Rebound Patient
Symptoms Include: Fatigue, Pins and Needles, Sensory Loss, Gastrointestinal Issues, Shortness of Breath, and Tachycardia A case study from a patient with Long Haulers who was recommended Tollovid by their...
Case Study 8: A Paxlovid Rebound Patient
Symptoms Include: Fatigue, Pins and Needles, Sensory Loss, Gastrointestinal Issues, Shortness of Breath, and Tachycardia A case study from a patient with Long Haulers who was recommended Tollovid by their...
-
Case Study #7: Acute and Long COVID Patient
Symptoms Include: Fatigue, Joint Pain, Fever, Clammy Hands, and Vision Issues A case study from a patient with Long Haulers who was recommended Tollovid by their physician Dr. Lee Morgentaler....
Case Study #7: Acute and Long COVID Patient
Symptoms Include: Fatigue, Joint Pain, Fever, Clammy Hands, and Vision Issues A case study from a patient with Long Haulers who was recommended Tollovid by their physician Dr. Lee Morgentaler....
-
Preliminary Data From IRB-Waived Tollovid® Mark...
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned joint venture 3CL Pharma Ltd.’s ongoing IRB-waived sponsored market research...
Preliminary Data From IRB-Waived Tollovid® Mark...
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from its majority-owned joint venture 3CL Pharma Ltd.’s ongoing IRB-waived sponsored market research...
Tollovid
Tollovid – Maximum Strength 3CL Protease Inhibitor
Share
